Qualified infectious disease product designation: What's to GAIN?

Navigating a dynamic study design in hepatitis B research

A major pharmaceutical company partnered with Fortrea for a Phase II platform study. The trial’s dynamic study design allowed for the addition and removal of study drugs in various treatment arms and combinations.

Successfully delivering an ultra-rare disease clinical trial in a competitive landscape

As an inherited, ultra-rare disease, limb-girdle muscular dystrophy type 2I (LGMD2I) is a common form of limb-girdle muscular dystrophy (LGMD), which causes weakness and loss of muscle mass, among other symptoms.

Recognizing the “new normal” of patient-centric clinical studies

While today the Drug Development Industry remains somewhat frustrated and concerned about the slow uptake of new technologies, such as eCo nsent, ePRO and Mobile Apps,

A new era of the clinical trial: How immuno-oncology advances are reshaping traditional clinical development paradigms

The traditional paradigm for clinical trial design is being upended, driven by an explosion in our understanding of cancer biology and the promise of an ever-growing array of advanced immunotherapy candidates.

Continuous innovation delivers faster, more efficient clinical trials

Innovative approaches help recruit and retain patients in a rare disease hematology study

A sponsor contracted Fortrea to run its Phase III hematology study and enroll 250+ patients with a rare disease in a highly competitive therapeutic area. Learn how Fortrea implemented collaborative strategies to address recruiting challenges, maximize retention and reduce patient burden with digital health innovation.

Designing an optimal long-term follow- up program for gene therapies and genetically modified cell therapies

Optimizing clinical trials for pediatric obesity treatment

Incorporating the voice of patient in pediatric assent forms